| Literature DB >> 30261847 |
Shuhui Cui1, Ruoyan Gai Tobe2,3, Xiuting Mo1, Xiaoyan Liu1, Lingzhong Xu1, Shixue Li1.
Abstract
After the publication of our article [1] we have been made aware of a number of mislabelling and reporting errors, which were introduced in the preparation of the manuscript. The conclusions are not affected by these errors and thus remain unchanged.Entities:
Year: 2018 PMID: 30261847 PMCID: PMC6161355 DOI: 10.1186/s12879-018-3370-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
ᅟ
| Baseline | Plausible range for sensitivity analysis | Sources | ||
|---|---|---|---|---|
| Parameters | ||||
| Discount rate | 0.03 | 0 | 0.03 | [31] |
| Vaccine coverage | 25.3% | 10% | 28.6% | [36, 37] |
| Mortality rate | 0.0058% | 0.000029 | 0.000039 | [41] |
| Rotateq efficacy | 98% | 0.883 | 1 | [38, 42] |
| Rotateq infected | 0.018% | 0 | 0.00018 | [42] |
| hospitalization1a | 44% | 0 | 0.44 | [22] |
| Outpatient1 a | 28% | 0 | 0.28 | [22] |
| Home-care1 a | 28% | 0 | 0.28 | [22] |
| Rotarix infected | 0.1% | 0 | 0.001 | [26] |
| LLR infected | 0.9% | 0 | 0.009 | [41] |
| hospitalization3c | 0.2% | 0 | 0.002 | [2] |
| Outpatient3 c | 7.9% | 0 | 0.079 | [2] |
| home-care3 c | 91.9% | 0 | 0.919 | [2] |
| Rotarix efficacy | 96.1% | 0.871 | 1 | [25, 26] |
| LLR efficacy | 72% | 0.63 | 0.79 | [27] |
| Infection rate | 78.85% | 0 | 0.7885 | [21, 45] |
| home-care2b | 32% | 0 | 0.32 | [22] |
| hospitalization2 b | 33% | 0 | 0.33 | [22] |
| Outpatient2 b | 35% | 0 | 0.35 | [22] |
| natural protact1d | 77% | 0 | 0.77 | [23] |
| natural protact2 d | 83% | 0 | 0.83 | [23] |
| Costs | ||||
| International vaccinations | 200.00 | 50 | 250 | [16, 17] |
| LLR vaccination | 24 | The national tariff | ||
| Hospitalizations | 570.04 | 0 | 570.04 | [43] |
| Outpatient | 104.19 | 0 | 104.19 | [43] |
| Home-care | 11.52 | 0 | 11.52 | [44] |
| Health Effects | ||||
| QALY(Hospitalization) | 0.077 | 0.075 | 0.078 | [30] |
| QALY(Outpatient) | 0.081 | 0 | 0.081 | [30] |
| QALY(Home-care) | 0.082 | 0 | 0.082 | [30] |
Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no intervention
| Strategy Name | Cost | QALYs | Incremental cost-effectiveness ratio ($/QALY) |
|---|---|---|---|
| No vaccine | 2379.945 | 17.71296 | (−) |
| LLR vaccine | 2507.851 | 22.65899 | 0 |
| Rotarix vaccination | 5982.187 | 24.31454 | 2105.66 |
| Rotateq vaccination | 5577.902 | 24.44506 | 1715.14 |